Chemotherapy for advanced ovarian cancer: Overview of randomized trials

Seminars in Oncology

Volumn 27, Issue 3 SUPPL. 7, 2000, Pages 11-16

  Thigpen, J T ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SALVAGE THERAPY;

EID: 0033886822     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Current status of the treatment of gynecologic cancer by site: Ovary
2. Chemotherapy of ovarian cancer: Past and present
3. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus Adriamycin plus cyclophosphamide in ovarian carcinoma
4. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: A Gynecologic Oncology Group study
5. cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary: A phase II study of the Gynecologic Oncology Group
6. Phase II study of cis-dichlorodiammineplatinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary
7. Chemotherapy of advanced ovarian cancer
8. Chemotherapy in advanced ovarian carcinoma: Current standards of care based on randomized trials
9. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study
10. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma
11. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cydophosphamide in advanced ovarian cancer
12. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer
13. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer
14. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials
15. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials
16. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma
17. Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer
18. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
19. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study
20. Phase I trial of Taxol in patients with advanced cancer
21. Sequences of Taxol and cisplatin: A phase I and pharmacologic study
22. ICON 2 and ICON 3 data in previously untreated ovarian cancer: Results to date
23. A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 Patients randomised into the 3rd International Collaborative Ovarian Neoplasm study (ICON3)
24. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
25. Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study 132
26. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study
27. Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Ov Ca)? The EORTC-GCCG, NOCOVA, NCI-C and Scottish Intergroup experience
28. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial
29. NCCN Ovarian Cancer Practice Guidelines
30. Update of the NCCN Ovarian Cancer Practice Guidelines
31. First-line chemotherapy for advanced ovarian cancer: Paclitaxel, cisplatin and the evidence
32. The role of anthracyclines in epithelial ovarian cancer